Telix Secures US$40M Upfront in Regeneron Radiopharmaceutical Partnership

Telix secures US$40 million upfront in Regeneron radiopharmaceutical partnership

Telix Pharmaceuticals has announced a strategic collaboration with global biotech Regeneron Pharmaceuticals to co-develop and commercialise next-generation radiopharmaceutical therapies. The deal delivers US$40 million upfront to Telix for four initial therapeutic programmes, with a 50/50 cost and profit-sharing structure designed to advance biologics-based radiopharmaceuticals for solid tumours.

The partnership combines Telix’s radiopharmaceutical development platform and global manufacturing infrastructure with Regeneron’s antibody discovery expertise and oncology portfolio. Regeneron, which holds a market capitalisation exceeding US$100 billion, represents a significant validation partner for Telix’s manufacturing capabilities and platform approach.

Key deal terms include:

• US$40 million upfront payment for access to Telix’s radiopharmaceutical manufacturing platform
• Four initial therapeutic programmes targeting multiple solid tumours
• Option for Regeneron to expand to four additional programmes with further upfront payments
• Up to US$2.1 billion in aggregate milestone payments if Telix opts out of co-funding across all programmes
• Low double-digit royalties on future net sales under the opt-out pathway

The collaboration structure provides Telix with strategic optionality on a per-programme basis. The company can choose to co-fund development and share profits equally, or elect to receive milestone payments and royalties instead. This flexibility enables Telix to balance capital deployment across its broader pipeline whilst maintaining upside exposure to programme success.

For investors, the deal represents non-dilutive capital strengthening Telix’s balance sheet whilst positioning the company as a platform partner for large-cap biotechnology firms seeking radiopharmaceutical capabilities.

What makes this collaboration strategically significant

The partnership pairs complementary strengths across the radiopharmaceutical development chain. Telix contributes its radiopharmaceutical development expertise, established global manufacturing capacity, and supply chain infrastructure built to support commercial-scale production. Regeneron brings its VelocImmune antibody discovery platform, bispecific antibody capabilities, and deep oncology development experience.

The collaboration will draw on multiple solid tumour targets from Regeneron’s antibody portfolio, generated using its proprietary VelocImmune technology. This platform produces fully human antibodies and bispecific antibodies, potentially enabling next-generation radiopharmaceuticals with improved targeting profiles compared to current generation therapies.

Both companies plan to jointly develop radio-diagnostics alongside therapeutic programmes. These diagnostic agents support patient selection by identifying which individuals are likely to respond to treatment, and enable assessment of treatment response during therapy. Telix will lead commercialisation of diagnostic assets, with Regeneron receiving a set percentage of profits.

The biologics-based approach represents an emerging frontier in radiopharmaceuticals. Traditional radiopharmaceuticals often use small molecules or peptides as targeting vectors. Antibody-based radiopharmaceuticals potentially offer improved specificity for tumour targets and more favourable biodistribution profiles, though they remain earlier in clinical validation compared to peptide-based agents.

Deal economics breakdown

The agreement provides Telix with two pathway options for each programme, enabling flexible capital allocation based on programme risk-reward profiles and portfolio priorities:

1. Co-funding pathway: Telix and Regeneron share development costs and commercialisation expenses equally on a 50/50 basis. Both companies share profits equally from successful products. Telix retains the option to co-promote certain products under this model.

2. Opt-out pathway: Telix can elect to step back from co-funding on a per-programme basis. Under this structure, Telix receives up to US$535 million in development and commercial milestones per programme, plus low double-digit royalties on future net sales.

Across all programmes, if Telix were to opt out of co-funding for all eight potential therapeutic programmes (four initial plus four optional), the aggregate milestone opportunity totals US$2.1 billion before royalties.

For diagnostic assets developed jointly, Telix leads commercialisation activities and Regeneron receives a set percentage of profits. This structure recognises Telix’s established commercial infrastructure in the radiopharmaceutical diagnostics market.

Understanding radiopharmaceutical partnerships

Radiopharmaceuticals are drugs that combine a radioactive isotope with a targeting molecule designed to deliver radiation directly to diseased tissue, typically cancer cells. Unlike external beam radiation therapy, radiopharmaceuticals circulate through the body and concentrate in tumours based on biological targeting mechanisms.

Manufacturing radiopharmaceuticals requires specialised infrastructure. Production facilities must handle radioactive materials under strict regulatory oversight, manage isotope decay timelines (many isotopes have short half-lives measured in hours or days), and coordinate complex supply chains linking isotope production sites with manufacturing facilities and clinical sites.

Large pharmaceutical and biotechnology companies typically partner with radiopharmaceutical specialists rather than building this infrastructure internally. The capital investment required for radioisotope production facilities, hot cell manufacturing suites, and regulatory expertise represents a significant barrier to entry. For companies with strong antibody or small molecule platforms but no radiopharmaceutical experience, partnering with established players provides faster market access.

Telix has built global manufacturing capacity including facilities in Belgium and the United States, alongside an isotope supply chain supporting both commercial products and clinical programmes. This infrastructure positions the company as a platform partner for organisations seeking to enter the radiopharmaceutical space without replicating these capabilities independently.

The Regeneron collaboration demonstrates platform monetisation potential beyond Telix’s proprietary pipeline. By providing manufacturing access and development expertise to external partners, Telix can generate upfront payments, milestone revenues, and profit-sharing opportunities whilst leveraging existing infrastructure across multiple programmes simultaneously.

What leadership says about the collaboration

Christian Behrenbruch, Managing Director and Group CEO at Telix, positioned the partnership as an opportunity to advance biologics-based radiopharmaceuticals:

Christian Behrenbruch, Managing Director and Group CEO, Telix

“The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients. We are well positioned to work toward the shared goal of advancing next generation precision radiopharmaceuticals for patients with hard-to-treat cancers.”

John Lin, Senior Vice President of Oncology & Antibody Technology Research at Regeneron, highlighted the collaboration as entry into the targeted radiopharmaceutical space: “Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need.”

Israel Lowy, Senior Vice President, Clinical Development Unit Head, Oncology at Regeneron, noted specific interest in lung cancer applications. “Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care,” Lowy stated.

The reference to Regeneron’s PD-1 inhibitor suggests potential combination development strategies pairing radiopharmaceutical therapies with checkpoint inhibitors, an approach being explored across multiple radiopharmaceutical programmes industry-wide.

Next steps and strategic outlook

The collaboration launches with four therapeutic programmes, providing near-term development catalysts as these advance through preclinical and clinical stages. Regeneron holds the option to expand the partnership to include four additional programmes with corresponding upfront payments to Telix, creating potential for further non-dilutive capital inflows.

Programme-level decisions on co-funding versus milestone pathways will likely occur as candidates progress toward clinical development, enabling Telix to assess risk-reward profiles with more complete data. This staged decision-making preserves optionality whilst maintaining partnership momentum.

The joint diagnostic development component positions Telix to leverage its commercial diagnostics infrastructure, with potential for earlier revenue generation compared to therapeutic programmes. Diagnostic candidates typically face shorter development timelines and lower regulatory hurdles than therapeutic agents.

For Telix shareholders, the deal establishes multiple future catalysts across programme initiation, clinical trial readouts, regulatory submissions, and potential commercialisation milestones. The partnership structure means Regeneron’s antibody discovery engine and oncology development capabilities now flow toward radiopharmaceutical applications leveraging Telix’s manufacturing platform.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they drop, with the analysis already done for you.